Conference Track

Hepatitis and Opportunistic Coinfections

Source: CCO Independent Conference Coverage of the CCO Independent Conference Coverage of the 2008 ICAAC/IDSA Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

Worsening Liver Fibrosis in HIV/HBV-Coinfected Patients Predicted by Elevated ALT, HDV Coinfection, High CD4+ Cell Recovery
High Incidence of Latent TB Infection Associated With Long Duration of Injection Drug Use in Incarcerated HIV-Infected Individuals
HIV-Infected Patients Living in “High-Risk” Housing at Higher Risk for Community-Associated MRSA
Risk for CA-MRSA 6-Fold Higher Among HIV-Infected Patients vs HIV-Uninfected Patients in Cook County
Higher Incidence of MRSA Infection in HIV-Infected Patients Compared With Matched HIV-Uninfected Patients in Veterans Aging Cohort Study
IMPAACT Substudy: Zoster in HIV-Infected Children on HAART Prevented by Varicella Zoster Vaccination
TMC207 Safe and Effective Against Multidrug-Resistant Tuberculosis
No Improvement in TB Disease-Free Survival With Isoniazid Prophylaxis Among HIV-Infected Children in Sub-Saharan Africa
Dual Therapy With Tenofovir/Emtricitabine Provides Effective Suppression of HBV DNA in HIV/HBV-Coinfected Patients
DUET-1 and DUET-2: Etravirine Associated With Reduction in AIDS-Defining Events or Death in Highly Treatment–Experienced Patients
BENCHMRK-1 and -2: Trend Toward Lower Risk for AIDS-Defining Events and Death With Raltegravir vs Placebo in Treatment-Experienced Patients

Expert Analysis

Hepatitis and Opportunistic Coinfections

Faculty:

Richard E. Chaisson, MD
Sally Hodder, MD
Bruce Polsky, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Summarize recent clinical trial data on tuberculosis diagnosis, prophylaxis, and treatment
Discuss new findings on the association between immune reconstitution inflammatory syndrome and antiretroviral therapy
Identify risk factors for community-associated methicillin-resistant Staphylococcus aureus infection
Describe new data on the efficacy of antiviral regimens for HBV/HIV and HCV/HIV coinfection
Specify the relationship between virologic and clinical outcomes in 2 recent randomized clinical trials investigating new antiretroviral agents

CME CREDIT INFORMATION

Release Date: 01/06/09

Expiration Date: 01/05/10

Physicians: maximum of 1.0 AMA PRA Category 1 Credit™

Registered Nurses: 1.2 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.